BLFS · BioLife Solutions, Inc.
$38.61
+0.00% 2-day
End-of-day data · updated 2026-10-24
Market cap
$2B
Enterprise value
$2B
Trailing P/E
39.0
Forward P/E
117.0
Dividend yield
0.0%
Beta
1.82
Avg volume
1M
Employees
0K
Daily Change %
0.00%
5 Days Change
—
10 Days Change
—
30 Days Change
—
60 Days Change
—
Month to Day Change
—
Year to Day Change
—
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Technical data is temporarily unavailable for BLFS.
Analyst sentiment over time — BLFS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-10
Latest call per bank · past 12 months
Jefferies
Hold$31.00
-19.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-10 | Benchmark | Downgrade | Buy → Hold | $0.00 |
| 2026-07-27 | Stephens & Co. | Downgrade | Overweight → Equal-Weight | $32.00 → $31.00 |
| 2026-07-23 | Jefferies | Downgrade | Buy → Hold | $30.00 → $31.00 |
| 2026-07-23 | TD Cowen | Downgrade | Buy → Hold | $33.00 → $31.00 |
| 2026-07-22 | Lake Street | Downgrade | Buy → Hold | $33.00 → $31.00 |
| 2026-07-22 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $32.00 → $31.00 |
| 2025-12-29 | HC Wainwright & Co. | Reiterates | Buy | $32.00 |
| 2025-11-24 | HC Wainwright & Co. | Reiterates | Buy | $32.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
BLFS Price Chart
Loading chart for BLFS…
Fundamentals
About BioLife Solutions, Inc.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$160B -21.6% YTD
BDX
Becton, Dickinson and Company
$54B 33.9% YTD
MDLN
Medline Inc.
$46B -17.0% YTD
RMD
ResMed Inc.
$36B 5.9% YTD
ALC
Alcon Inc.
$34B -9.9% YTD
WST
West Pharmaceutical Services, I
$28B 43.5% YTD
SOLV
Solventum Corporation
$15B 10.4% YTD
BAX
Baxter International Inc.
$13B 34.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.